Claims for Patent: 8,871,450

Summary for Patent: 8,871,450

Title:	Biomarker for colorectal cancer
Abstract:	The present invention relates to new methods for predicting the clinical outcome or determining the treatment course in a subject afflicted with solid tumors, like colorectal cancer, and for monitoring the progression of solid tumors, like colorectal cancer, in a subject. Moreover, the present invention relates to a method for stratification of therapy regimen of a subject afflicted with solid tumor entities, such as colorectal cancer, for determining its susceptibility to the treatment with an inhibitor of angiogenesis. Further, the present invention relates to kits allowing performance of the above methods. In particular, the present invention is based on the finding that determining the level or amount of angiopoietin-2 protein in a sample of a subject is useful for conducting the above referenced methods.
Inventor(s):	Hacker; Ulrich (Cologne, DE), Goede; Valentin (Cologne, DE), Coutelle; Oliver (Cologne, DE)
Assignee:	Universitat zu Koln (Cologne, DE)
Application Number:	13/390,532
Patent Claims:	1. A method for treating a solid tumor in a subject with advanced colorectal cancer, comprising determining a level of angiopoietin-2 (Ang-2) in a sample of body fluid obtained from said subject with advanced colorectal cancer prior to treatment for the solid tumor; and a) if said level of Ang-2 is less than 3.5 ng/ml, then treating said subject by administering to said subject chemotherapy that includes an inhibitor of angiogenesis; and b) if said level of Ang-2 is equal to or greater than 3.5 ng/ml, then treating said subject by administering to said subject chemotherapy that does not include an inhibitor of angiogenesis. 2. The method of claim 1, wherein said inhibitor of angiogenesis is a vascular endothelial growth factor (VEGF) inhibitor. 3. The method of claim 2, wherein said VEGF inhibitor is an antibody. 4. The method of claim 2, wherein said antibody is the VEGF antibody bevacizumab. 5. The method of claim 1, wherein said determining step is performed multiple times. 6. The method of claim 1, wherein said sample of body fluid is a urine or blood sample. 7. The method of claim 1, wherein the level of Ang-2 is determined at the protein level. 8. The method of claim 1, wherein the level or amount of Ang-2 is determined by immunological methods. 9. The method of claim 8, wherein said immunological method is an ELISA. 10. The method of claim 1, further comprising a step of resectioning said solid tumor.

Details for Patent 8,871,450

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2029-09-07